Tradition Chinese medicine (TCM) has good clinical application prospects in diabetes treatment. In addition, TCM is less toxic and/or has fewer side effects and provides various therapeutic effects. Berberine (BBR) is isolated as the main component in many TCM kinds (e.g., *Rhizoma Coptidis* and *Berberidis Cortex*). Furthermore, BBR can reduce blood sugar and blood fat, alleviate inflammation, and improve the state of patients. Based on the recent study results of BBR in diabetes treatment, the BBR pharmacokinetics and mechanism on diabetes are mainly studied, and the specific molecular mechanism of related experimental BBR is systematically summarized and analyzed. Clinical studies have proved that BBR has a good therapeutic effect on diabetes, suggesting that BBR may be a promising drug candidate for diabetes. More detailed BBR mechanisms and pathways of BBR need to be studied further in depth, which will help understand the BBR pharmacology in diabetes treatment.

However, the low BBR bioavailability and the unclear mechanism of action are the problems where its clinical application is greatly limited. This article aims to study the BBR pharmacokinetics and roughly explains the changes under the influence of the body after BBR administration to clarify the reasons for the BBR poor absorption and propose solutions to provide new formulations with high bioavailability in the future. Simultaneously, by summarizing the molecular mechanism of antidiabetic BBR, many pathway studies were noted to be relatively superficial. Thus, a more in-depth study is needed to determine its detailed mechanism to provide a reference for subsequent animal and human experimental designs [1–3].

2. Pharmacokinetic BBR Profile

2.1. Absorption. BBR has a good therapeutic effect on various diseases, but its clinical application is limited to a certain extent because of its poor oral absorption and low bioavailability [3, 4]. In terms of clinical medication,
although intravenous injection can increase the drug concentration in the blood, clinical trials found that it will cause serious side effects (e.g., drop in blood pressure and respiratory arrest). Thus, oral administration is the main clinical BBR administration method. However, the absolute BBR bioavailability in rats is <1%. The poor absorption after BBR oral administration is caused by poor permeability, P-glycoprotein- (P-gp-) mediated efflux, hepatobiliary reexcretion, and self-aggregation. Moreover, the low BBR oral bioavailability may be due to its poor absorption and the first-pass effect in the liver as well as in the intestine [5].

Previous experiments have proved that the BBR bioavailability can be improved in various ways. On the one hand, altering the delivery system is a pretty good way to improve bioavailability. On the other hand, the BBR chemical structure modification, especially the synthesis of derivatives with an antidiabetic effect, is also a common approach for improving BBR’s efficacy [6]. Additionally, some experiments [7] proved that the coadministration of BBR and P-gp inhibitors was also effective. The specific examples of the three aforementioned methods are shown in Table 1. Furthermore, Cui et al. found that the bioavailability of berberine organic acid salts, especially BBR fumarate and BBR succinate, is higher than that of BBR hydrochloride [8]. Therefore, fully considering the different BBR administration forms to fully exert the BBR pharmacological effects is necessary for the clinical application process.

2.2. Distribution. Some studies [27, 28] revealed that BBR is mainly distributed in tissues after oral administration with lower plasma content. After intragastric dosing, BBR was rapidly distributed in the liver, kidneys, muscle, lungs, brain, heart, pancreas, and fat in descending amount order. Thus, the liver is the main distribution organ. The pharmacokinetic profile indicated that the BBR level in most of the studied tissues was about 70 times higher than that in plasma 4 h after administration. However, it remained relatively stable in tissues (e.g., liver, muscle, brain, heart, and pancreas).

2.3. Metabolism. Numerous experimental studies have confirmed that BBR has a quick metabolic rate in vivo, which is mainly metabolized by the liver and intestinal flora. Moreover, most of it is metabolized into other components. Therefore, BBR content and structure will change accordingly after BBR is metabolized by the liver and intestinal flora. The major metabolic BBR pathways were demethylation, demethylation, reduction, and hydroxylation (phase I BBR metabolites), and subsequent glucuronidation, sulfation, and methylation (phase II BBR metabolites) were the major metabolic BBR pathways in vivo [29–31].

Earlier studies have demonstrated that BBR metabolism is closely related to the cytochrome P450 (CYP450) enzymes in the liver [11]. Studies on BBR metabolism have shown that BBR can be metabolized by CYP450 enzyme subtypes, of which the most significant metabolic enzymes are CYP2D6 and CYP1A2, which play a crucial role in BBR biotransformation in mice and humans [32, 33]. After 0.5 h and 1 h after oral administration of BBR and original drug, the main metabolites and their respective glucuronic acid conjugates were detected in the liver tissues and bile, respectively [28].

The intestine is the main part of oral administration for absorption and metabolism. As an invisible “organ” in the body, the gut microbiota is the main participant. Previous studies have indicated that BBR undergoes a series of biotransformation processes in vivo after oral administration under the action of the gut microbiota, and its property and content have changed, which may be affected by the intestinal flora. Previous experiments [34, 35] have demonstrated that the main metabolites produced by BBR after the intestinal flora conversion are two types of demethoxy and hydrogenation. The BBR hydrogenation metabolic pathway is BBR can be metabolized by nitroreductases (NRs) produced by the intestinal flora into its absorbable form of dihydroberberine, which then oxidizes back to BBR after absorption in intestine tissues and enters the blood. Studies on this process are conducive to the more in-depth elucidation of the material basis of the drug’s effect.

2.4. Excretion. BBR is mainly excreted in the kidneys (urine and feces) and bile in different animals. Bile excretion is slow due to the presence of hepatenteric circulation. Experiments have proved that the different experimental subjects (rabbits, mice, rats, and humans) and different BBR administration methods (gavage, oral, and intravenous administration) will both cause excretion differences.

According to relevant experimental studies [36, 37], it is not difficult to find that, for rats, feces are the main excretion method during gavage or oral administration, and BBR in feces is mainly excreted in its original form. However, urine and bile excretion are the opposite. Their excretion is much lower than feces, and the excretion of BBR metabolites is greater than the prototype. Urine is the main excretion method when intravenously administered. For instance, BBR and many of its metabolites were quantitatively detected by high-performance liquid chromatography-tandem mass spectrometry. The total recovered BBR rate was 22.83%. The recovered rate of the prototype was more than fivefold that of its metabolites, while the BBR excretion in descending order was feces > urine > bile. Additionally, most BBR and its metabolites were found in the feces containing 84% of the prototype.

As for mice, the experiment [33] proved that BBR (I), the prototype administered, was the most abundant compound in urine, and urine excretion amount was about twofold that in feces. In addition, 11 metabolites were detected in feces and urine: six conjugated (metabolites III, V, VIII, IX, X, and XI) and five unconjugated (metabolites II, IV, VI, VII, and XII) metabolites.

3. Studies on the BBR Mechanism

Streptozotocin (STZ) is toxic to β-cells and can be used to induce diabetes models. In this rat model, BBR shows significant β-cell regeneration, insulin secretion, insulin sensitization, and antioxidant activity [38]. Therefore, most of
the various mechanisms described below are discussed based on the STZ-induced diabetic model. BBR has a good effect on metabolic syndrome such as diabetes [39–41]. It does not only lower blood sugar by enhancing insulin sensitivity, promoting insulin secretion, protecting islet cells, stimulating glycolysis in peripheral tissue cells, inhibiting gluconeogenesis in the liver, and anti-insulin resistance (IR) but also improves the symptoms of inflammation, oxidative stress, and lipid metabolism disorders in diabetic patients by anti-inflammatory, antioxidant, antiapoptotic, and lipid metabolism disorder regulation. In addition, studies have shown that BBR can regulate intestinal flora to maintain the stability of the intestinal environment. The various methods of BBR diabetes treatment are shown in Figure 1.

### 3.1. Antihyperglycemic

Diabetes mellitus is a metabolic disease characterized by high blood sugar caused by defective insulin secretion or impaired insulin action. The prerequisite for diabetes treatment by lowering blood sugar is to understand the source and destination of blood sugar and how to regulate blood sugar concentration. BBR can weaken blood sugar source by inhibiting liver gluconeogenesis and strengthen glucose metabolism by inducing glycolysis. In addition, BBR can also regulate blood glucose concentration by enhancing insulin sensitivity, reducing IR, and promoting insulin secretion. The specific BBR-related pathways and molecular mechanisms in lowering blood sugar are shown in Figure 2. In addition, the animal and cell experiments of BBR’s hypoglycemic effect are summarized in Table 2.

### Table 1: Summary of ways and examples to improve the bioavailability of BBR.

| Methods                          | Examples                                                                 | Effect                                | References |
|----------------------------------|--------------------------------------------------------------------------|---------------------------------------|------------|
| Alternative delivery system      | Dendrimer encapsulated and conjugated delivery of BBR                    | Improved BBR oral bioavailability     | [9]        |
|                                  | Clear anhydrous reverse micelles containing amorphous BBR nanoparticles  | Enhanced the hypoglycemic effect      | [10]       |
|                                  | BBR nanosuspension                                                       | Improved lipid metabolism, lowered blood sugar | [11]       |
|                                  | Selenium-coated nanostructured lipid carriers                            | Increased intestinal absorption, improved the hypoglycemic effect | [12]       |
|                                  | Polymer-lipid hybrid nanoparticles loaded with BBR-phospholipid complex | Enhanced the oral efficiency, improved sustained release | [13]       |
|                                  | BBR-loaded solid lipid nanoparticles                                     | Strengthened intestinal absorption, enhanced the antidiabetic effect | [14]       |
|                                  | A novel BBR-loaded cremochylomicron                                      | Improved BBR oral bioavailability     | [15]       |
| Chemical structure modification  | The mannose modified BBR derivative                                      | Increased antidiabetic activity        | [16]       |
|                                  | Synthesis of disaccharide modified BBR derivatives                        |                                        | [17]       |
|                                  | BBR derivative: nandinine                                                | Inhibited inflammation, attenuated IR | [18]       |
|                                  | BBR derivative: dihydroberberine                                          | Enhanced insulin sensitivity, attenuated IR | [19]       |
|                                  | 9-O (lipophilic group substituted) BBR derivatives                        | Increased hypoglycemic activity        | [20]       |
|                                  | C-9 modified BBR derivatives                                              | Improved lipid-lowering activity       | [21]       |
| Coadministration with P-gp inhibitors | D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)               | Decreased the efflux rate of BBR, promoted intestinal absorption | [22]       |
|                                  | Glycine (GLY)                                                            |                                        | [23]       |
|                                  | Cyclosporine A (CsA)                                                     |                                        | [24]       |
|                                  | Oligomeric proanthocyanidins (OPCs)                                      |                                        | [25]       |

![Figure 1: The various methods of BBR treatment of diabetes (↑ = increase or improve; ↓ = decrease or inhibit).](image-url)
cardiomyocytes by activating AMPK [68]. Two main BBR mechanisms were noted to activate the AMPK pathway. One is that BBR inhibits respiratory complex I of the mitochondrion, thereby stimulating the AMPK activity [19, 65]. The other is that BBR upregulated the expression of sirtuin 1 (SIRT1) in adipose tissue so that the AMPK pathway can be activated [69]. Eventually, the effects of inhibiting inflammation, ameliorating IR, and increasing insulin sensitivity are achieved.

The insulin receptor (InsR), a vital factor in the insulin signaling pathway, is extremely important for the physiological effects of insulin on cells [70]. BBR could increase the activity of InsR mRNA and upregulate protein kinase C-dependent InsR expression, thereby effectively increasing glucose utilization and improving IR [42–44]. Simultaneously, BBR had the ability to upregulate InsR gene expression muscle cells and in the liver in a protein kinase D-(PKD-) dependent manner, which contributed to promoting insulin sensitivity [71]. BBR behaved like an insulin sensitizer in these mechanisms to some extent.

In addition, experiments illustrated that BBR alleviated IR by regulating the expression of genes related to metabolism in the liver of diabetic rats. Specifically, BBR could not only upregulate the mRNA levels in the expression of liver X receptor and peroxisome proliferator-activated receptors but also downregulate the expression of sterol-regulatory element-binding proteins and PPAR-γ, which improved fat-induced hepatic IR [45, 46]. Furthermore, BBR alleviated IR through fibroblast growth factor 21 (FGF21). FGF21 is a hormone derived from the liver that exerted important effects on regulating body metabolism. In IR mice, BBR could regulate glucose metabolism and increase insulin sensitivity through

Figure 2: The main pathways and molecular mechanisms of BBR in lowering blood sugar (↑ = increase or improve; ↓ = decrease or inhibit).
mechanisms such as inducing FGF21 production and secretion and promoting white fat browning \[48, 72\]. In the myotube IR model, BBR administration activated the phosphatidylinositol 3-kinase (PI3K) pathway, which in turn increased GLUT4 translocation and acute insulin-mediated glucose transport, thereby alleviating IR \[47\]. Furthermore, BBR inhibited the protein tyrosine phosphatase 1B activity of mice embryonic fibroblasts 3T3-L1 adipocytes in a dose-dependent manner, thereby improving IR \[49\]. In addition, BBR inhibited the lipopolysaccharide (LPS)/toll-like receptor 4 (TLR4)/tumor necrosis factor-α (TNF-α) pathway, suggesting that this pathway may be one of the BBR mechanisms to lower blood glucose and moderate IR \[50\]. Moreover, Wu et al. demonstrated that BBR may alleviate IR via regulation on the protein phosphatase, Mg2+/Mn2+-dependent 1B (PPM1B) signaling pathway, including the PPM1B/Inhibitor kappa B kinase (IκB)/nuclear factor κB (NF-κB), and PPM1B/GLUT4 pathways \[51\].

3.1.2. Promoting Insulin Secretion. BBR can promote insulin secretion with a hypoglycemic effect by pancreatic β-cells \[73\]. The main mechanism is discussed in the following sentences. Moreover, BBR may stimulate insulin secretion mainly through improving PARP-1 protein expression and pancreatic β-cells proliferation \[52\]. Besides, as a hormone secreted by the intestinal tract, glucagon-like peptide-1 (GLP-1) has a variety of physiological functions, such as stimulating insulin secretion, promoting the proliferation of pancreatic β-cells, and regulating glucose metabolism. Furthermore, BBR could increase the secretion and synthesis of GLP-1 when blood sugar is elevated, thereby promoting insulin secretion in cells and regulating insulin level in the body \[53\].

| Effects of BBR | Animal model and cells type | Dosage and usage of BBR | References |
|----------------|-----------------------------|-------------------------|------------|
| Increasing insulin sensitivity and alleviating IR | HFD mice and rats | In vivo, 100 mg/kg/d (p.o. for 2 weeks) | \[19\] |
| | HFD mice with or without Sirt1 knockout | In vivo, 20 or 50 mg/kg/d (p.o. for 2 weeks) | \[42\] |
| | HFD + STZ T2DM rats; HepG2 cells | In vivo, 75 or 150 mg/kg twice a day (p.o.); in vitro, 1 nmol/L of insulin or 7.5 μg/mL of BBR | \[43\] |
| | HFD + STZ T2DM rats | In vivo, 200 mg/kg/d (p.o.) | \[44\] |
| | STZ T2DM rats | In vivo, 75, 150, 300 mg/kg/d (p.o. for 16 weeks) | \[45\] |
| | HFD + STZ T2DM hamsters | In vivo, 150 mg/kg/d (p.o. for 9 weeks) | \[46\] |
| | L6myc cells | 7.5 μg/mL of BBR (for 1h) | \[47\] |
| | HHF fed mice with SIRT1 LKO | In vivo, 5 mg/kg/d (i.p. for 5 weeks) | \[48\] |
| | db/db mice and DIO mice; 3T3-L1 adipocytes L6 myocytes | In vivo, 100 mg/kg/d (p.o. for 2 weeks); in vitro, 1.25 μM and 1.5 μM; in vitro, 2.5-5 μM | \[49\] |
| | HFD and SPF rats | In vivo, 100 mg/kg/d (i.p. for 8 weeks) | \[50\] |
| | HFD and ZDF rats | In vivo, 100 or 300 mg/kg/d (i.p. for 12 weeks) | \[51\] |
| Promoting insulin secretion | HFD + STZ T2DM rats | In vivo, 100 mg/kg/d (i.p. for 8 weeks) | \[52\] |
| | Rats fed with commercial stock diet; human NCI-H716 cells | In vivo, 60 or 120 mg/kg/d (p.o. for 5 weeks); in vitro, 0, 1, 10 and 100 μM | \[53\] |
| | Rats insulinoma INS-1E cells with HG | In vivo, 0, 1, 5 and 10 μmol/L | \[54\] |
| | Rat pancreatic islets | In vitro, 1, 3, 10 and 30 μmol/L | \[55\] |
| | Rat islets | In vitro, 0, 0.5, 2.5, 5 and 10 μM for 1h | \[56\] |
| Promoting glucose uptake | 3T3-L1 fibroblasts | In vitro, 1-10 μM for 6h | \[57\] |
| | HFH diabetic hamsters | In vivo, 50 or 100 mg/kg/d (p.o. for 6 weeks) | \[58\] |
| | 293 T cells and primary hepatocytes | In vitro, 0, 1, 5 and 10 μM | \[59\] |
| | H9c2 cardiomyoblast cells | In vitro, 12.5 μM for 24h | \[60\] |
| Inducing glycolysis | HFD rats; 3T3-L1 preadipocytes and myoblasts L6 | In vivo, 125 mg/kg twice a day (i.p. for 5 weeks); in vitro, 0, 2 and 10 μmol/L | \[61\] |
| | HepG2 and mouse skeletal myoblast C2C12 | In vitro, 0, 2, 5 and 10 μM | \[62\] |
| | HepG2 hepatocytes and C2C12 myotubes | In vitro, 10 μM | \[63\] |
| Inhibiting gluconeogenesis in the liver | HFD + STZ diabetic rats | In vivo, 156 mg/kg/d (i.p. for 12 weeks) | \[64\] |
| | HFD + STZ diabetic rats | In vivo, 380 mg/kg/d (p.o. for 5 weeks) | \[65\] |
| | HFD + STZ diabetic rats | In vivo, 40 or 160 mg/kg/d (p.o. for 4 weeks) | \[66\] |

HFD: high-fat diet; HepG2: human hepatocellular carcinomas; SIRT1 LKO: liver-specific Sirt1 knockout; DIO: diet-induced obesity; HFHS: high fat, high sucrose; SPF: specific pathogen free; ZDF: Zucker diabetic fatty.

Table 2: Effects of BBR on antihyperglycemic in animals or cells with diabetes mellitus.
manner and significantly weakened insulin secretion at high glucose concentrations. Research on the mechanism of action in this area is relatively scarce. One possible mechanism is BBR inhibited GSIS via the KATP-dependent triggering pathway [56].

3.1.3. Promoting Glucose Uptake. Glucose relies on glucose transporters to enter the cell after glucose is absorbed into the blood. GLUT1 is expressed in all human tissues, and GLUT4 is mainly expressed in insulin-sensitive myocardium, skeletal muscle, fat cells, and myocardium. BBR can activate GLUT1 and upregulate GLUT1 expression level through the AMPK pathway and increase GLUT4 expression and translocation activity, thereby enhancing the glucose uptake and elevating the glucose availability by tissues and cells of the body [57–59]. For example, BBR enhanced the IRS1-Pi3-kinase-Akt signal cascade of adipocytes to increase GLUT4 content in the membrane, which was beneficial for glucose uptake promotion [74]. BBR also had a mechanism of promoting glucose uptake through the AMP-AMPK-p38 mitogen-activated protein kinase (MAPK) pathway rather than the insulin signaling pathways. Thus, BBR may stimulate glucose uptake and consumption via increased the production and accumulation of triacylglycerol and decrease cellular diacylglycerol (DAG) levels in H9c2 cells [60].

3.1.4. Inducing Glycolysis. AMPK was the main energy sensor, which was turned on when the glucose level rose and turned off when the glucose level fell. Experiments revealed that the BBR effect on lowering blood sugar did not necessarily depend on AMPK activation. In other words, BBR played a bidirectional role in regulating AMPK phosphorylation. Moreover, when the blood sugar rose in vivo, BBR played a beneficial role in stimulating glycolysis by inhibiting glucose oxidation in the mitochondria, which was associated with the inhibition of glucose oxidation in the mitochondria. Thus, AMPK activation may be caused by the increase in the AMP/ATP ratio due to mitochondrial inhibition [61]. In contrast, other scholars found that BBR stimulated glycolysis and improved sugar metabolism via inhibiting mitochondrial respiratory chain complex I, which did not depend on AMPK activation, in case of nonhypoglycemia [62, 63].

3.1.5. Inhibiting Gluconeogenesis in the Liver. Glucose-6-phosphatase (G6 Pase) and phosphoenolpyruvate carboxykinase (PEPCK) were two key rate-limiting enzymes that regulated hepatic gluconeogenesis through their transcriptional modulation [64]. BBR may inhibit mitochondrial function, and the expression of PEPCK, G6 Pase, and adipogenic genes that depend on ATP for energy supply is reduced, thereby inhibiting gluconeogenesis. Through inhibiting SIRT3, BBR could cause PEPCK1 instability to make the development of gluconeogenesis in the liver to be attenuated [59]. Beyond that, BBR inhibited liver gluconeogenesis in diabetic rats through the liver kinase B1-AMPK transcription coactivator 2 signaling pathway [53, 54]. BBR suppressed the HNF-4α miR122 pathway in type 2 diabetic mice, which contributed to the attenuation of gluconeogenesis and lipid metabolism disorder [66].

3.2. Antioxidant Stress and Anti-Inflammatory Response. Current studies have reported that BBR has a therapeutic effect on type 2 diabetes mellitus (T2DM) and its complications by affecting inflammation and oxidative stress. Numerous pieces in the literature showed that inflammation and oxidative stress had a close relationship. They have several common signal pathways. The vicious circle of the two will further cause IR. Similarly, the imbalance of the intestinal flora in diabetic patients will also lead to low-grade inflammation, oxidative stress, IR, and vice versa. In various tissues and cells related to metabolism, berberine could play an anti-inflammatory role through reducing the expression of key proinflammatory cytokines interleukin-6 (IL-6), interleukin-1β (IL-1β), and TNF-α. Similarly, research results confirmed that BBR exerted an indispensable influence on antioxidative stress by regulating antioxidant enzymes and oxidative stress markers [75]. BBR acted against oxidative stress and inflammation via an extremely complex mechanism consisting of some signaling pathways (including NF-κB, AMPK, nuclear factor erythroid-2-related factor-2 (Nrf2)/oxygenase, and MAPKs pathway), as well as various kinases in cells [76, 77]. The available data on BBR administration have revealed the close connection between oxidative stress and inflammation and different cellular pathways as illustrated in Figure 3. The animal and cell experiments of BBR administration that act against oxidative stress and inflammation are shown in Table 3.

As a kind of transcription factor, Nrf2 can stimulate the transcription of antioxidant- and anti-inflammatory-related genes. Moreover, PI3K/Akt, AMPK, and P38 signaling pathways all participated in the BBR-mediated antioxidant and anti-inflammatory responses. Through these signaling pathways, BBR activated the nuclear Nrf2 pathway so that it exerts many effects, including upregulating antioxidant enzyme superoxide dismutase (SOD), glutathione peptide (GSH), and glutathione peroxidase (GSH-Px) and inhibiting the generation of reactive oxygen species (ROS) and the expression of inflammation-related factors such as IL-1β, IL-6, TNF-α, cyclooxygenase-2 (COX2), and inducible nitric oxide synthase (iNOS), which contributed to the BBR antioxidant and anti-inflammatory activities [77, 81]. Increasing pieces of evidence currently proved that heme oxygenase-1 (HO-1), an antioxidant enzyme whose expression is regulated by Nrf2, is a vital molecule. BBR could induce HO–activation and exert comprehensive benefits on extenuating inflammation and oxidative stress [86]. Meanwhile, NF-κB was also a transcription factor that promoted the expression of inflammatory factors. BBR inhibited the transforming growth factor beta-activated kinase 1/NF-κB molecular signaling pathway via blocking the MAPK pathway and SIRT1-dependent mechanism and inhibited NF-κB phosphorylation, which led to attenuating secretion and IL-1β, IL-6, iNOS, COX2, and TNF-α expression and decreasing the ICAM-1 expression, thereby
Figure 3: Mechanistic aspects of the antioxidant and anti-inflammatory action of BBR (↑ = increase or improve; ↓ = decrease or inhibit; the blue rectangle represents the related pathway mechanism of inflammatory response; the green rectangle represents the related pathway mechanism of oxidative stress; and the orange color represents the related pathway mechanism of inflammatory response and oxidative stress).

Table 3: Effects of BBR on oxidant stress and inflammation in animals or cells with diabetes mellitus.

| Animal model, cell type | Samples examined | Dosage | Effects | References |
|-------------------------|------------------|--------|---------|------------|
| ddY mice, STZ 100 mg/kg, single i.p. injection | Liver | 200 mg/kg/d p.o. for 2 weeks | ↓: GPx; ↑: SOD | [78] |
| ICR mice, nicotinamide 1000 mg/kg + STZ 100 mg/kg, single i.p. injection | Liver and kidney | 100 mg/kg/d, p.o. for 2 weeks | ↓: MDA; ↑: SOD | [79] |
| ICR male mice, STZ 30 mg/kg, single i.p. injection | Serum and islets | 5 mg/kg/d, i.p. for 3 weeks | ↓: MDA; ↑: SOD | [80] |
| Male Wistar rats, ATO (arsenic trioxide) 7 mg/kg, p.o. | Mitochondria and hepatocytes | 100 mg/kg/d, p.o. for 8 days | ↓: ROS | [81] |
| RAW 264.7 macrophages treated with or without LPS | 264.7 macrophages | 1–20 μM pretreated for 4 hours before LPS treatment for 20 hours | ↓: IL-6, TNF-a | [82] |
| Male albino Wistar rats, STZ 40 mg/kg, single i.p. injection | Serum and liver | BC 50 mg/kg/d, i.p. for 45 days | ↓: TNF-a, COX-2, iNOS; ↑: SOD, GSH, GPx | [83] |
| RAW 264.7 macrophages treated with LPS | Culture media | BH 10, 20, and 40 μM for 0–48 h. | ↓: TNF-a, IL-6, IL-1β | [84] |
| RAW 264.7 macrophages treated with BBR or LPS | Culture media | 5 μM treated for 24 hours BBR mg/kg and LPS injection 15 mg/kg i.p. for 6 hours | ↓: IL-6, COX-2, iNOS, ROS | [85] |
| ICR mice with or without Nrf2 | Lung | | | |

↑ = increase or improve; ↓ = decrease or inhibit; BC: berberine chloride.
suppressing inflammation [59, 82, 83]. In addition, BBR could inhibit the IKK/NF-κB pathway and decrease the expression and secretion of inflammatory factors by inhibiting the activity of acetylcholinesterase in the cell supernatant. Except this, BBR could reduce TLR4 expression at mRNA and protein levels and the NF-κB activity, which resulted in anti-inflammatory effects [84]. Furthermore, BBR suppressed the transcription and expression of COX2 and AP-1 through attenuating PPAR-γ expression and phosphorylation [77].

Previous experiments have verified that BBR directly or indirectly inhibited MAPK in a way that is dependent or independent of AMPK activation in macrophages as well as decreased the expression of proinflammatory factors IL-1β, IL-6, monocyte chemoattractant protein-1, and COX2 [77, 82, 83, 85]. BBR could not only increase GSH, SOD, and GSH-Px contents but also decrease the marker of oxidative stress malondialdehyde (MDA) content. The regulation of these factors was beneficial in dealing with the problem of excessive free radicals in the oxidative stress response [76, 78, 79]. BBR ameliorated oxidative stress through increasing UCP2 and SOD, decreasing ROS and MDA production, and decreasing reduced coenzyme II NADPH oxidase expression. These may be mediated via the mitochondrial SirT3 pathway, miR-106b/SIRT1, SIRT1/FOXO (the forkhead box O), or AMPK pathway [77, 80].

3.3. Regulating the Lipid Metabolism Disorder. Fat accumulation plays a significant role in the occurrence and development of IR. Numerous experiments have confirmed that BBR had a pivotal role in regulating adipose tissues. BBR could significantly promote the conversion of liver cholesterol and the formation of bile acids and then stimulate its rapid excretion to bile to prevent lipid accumulation and rerelease of free fatty acids. Thus, the levels of low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), and serum total cholesterol significantly decreased and high-density lipoprotein cholesterol and NO levels significantly increased, suggesting that lipid catabolism was promoted [87–91]. By stimulating the low-density lipoprotein receptor (LDLR) expression activated by extracellular regulated protein kinases (ERK), BBR could stabilize low-density lipoprotein receptor (LDLR) mRNA, thus regulating the level of LDL-C [89, 90].

Furthermore, PPARs regulate the fat metabolism and fat differentiation processes as the main transcription factor of fat metabolism and differentiation. Experiments indicated that PPARγ mRNA expression is significantly reduced after BBR administration, thereby inhibiting the PPARγ transcriptional activity and inhibiting fat production. To be specific, BBR increased the PPAR α/δ and ATP binding cassette transporter A1 levels; downregulated the PPAR γ and PPAR γ co-activator-1 levels; and activated the c-Jun N-terminal kinases, AMPK-p38 MAPK-GLUT4, and PPARs pathways to moderate lipid metabolism [45, 92, 93]. The NR activity in the feces could be used as a biomarker for personalized hyperlipidemia treatment using BBR. According to reports, the NR of the intestinal bacteria is a key factor to promote BBR intestinal absorption. Also, the regulation of the NR activity in the intestine by BBR may be one of its lipid-lowering mechanisms [94].

3.4. Regulating Gut Microbiota. The ecological balance of the intestinal flora will have a significant impact on the therapeutic effect of drugs. Drug prototypes and their metabolites will have a certain impact on the number and abundance of the intestinal flora, resulting in changes in intestinal homeostasis, thus affecting disease occurrence and development [95]. Current studies have shown that metabolic syndrome is closely related to the role of intestinal flora, and abnormal metabolism of substances mediated by intestinal flora is a significant pathological mechanism of metabolic syndrome. Due to the low BBR bioavailability, the classical pharmacokinetic theory is not enough to fully explain its hypoglycemic effect. Therefore, many scholars believe that the BBR hypoglycemic effect is not produced after absorption, but plays a role in the intestine [33]. Chen et al. [96] showed that BBR did have the ability to regulate the intestinal flora, protect the intestinal mucosal barrier, resist inflammation, and inhibit glucose absorption. Moreover, Xu et al. demonstrated that BBR treatment significantly altered the overall intestinal microbiota structure and enriched many butyrate-producing bacteria, thereby reducing blood sugar levels and alleviating inflammation [97]. Through the regulation of these flora, the levels of blood lipids and blood sugar in patients with metabolic diseases can improve, and it has a positive effect on the treatment of obesity, hypertension, T2DM, and other diseases.

The intestinal microecological imbalance in patients with T2DM is mainly manifested by changes in the composition, abundance, and function of the intestinal flora. More than 90% of the human intestinal flora are phylum Firmicutes and Bacteroidetes, which can be divided into three categories: beneficial bacteria (Bifidobacterium, Bacteroides, Lactobacillus, Blautia, and so on), conditional pathogenic bacteria (Enterococcus, Escherichia coli, and so on), and harmful bacteria (Staphylococcus, Proteus, and so on) [98, 99]. Among them, Bifidobacterium and Lactobacillus can improve the level of inflammatory factors. In addition, blood lipids can also be reduced and antihypertensive substances (e.g., angiotensin-converting enzyme inhibitory peptides), which can directly or indirectly reduce blood pressure and improve the level of blood lipids in patients, can be produced. Firmicutes can increase the absorption of carbohydrates and fat in the human intestine (called fat bacteria), while the role of Bacteroides is just the opposite (called lean bacteria). The decrease of the ratio of Firmicutes/Bacteroides can inhibit the growth of Enterococcus faecalis in the intestinal tract and simultaneously promote the growth of beneficial bacteria and suppress the incidence of obesity. After BBR treatment, the abundance of Blautia and Bacteroides increased and the abundance of Faecalibacterium prausnitzii and Escherichia coli decreased. Meanwhile, the ratio of Bacteroides/Firmicutes restoration resulted in decreasing levels of blood sugar and blood lipids, as well as IR improvement [87, 100–102].
BBR mainly affects the short-chain fatty acid metabolism, bile acid metabolism of the intestinal flora, and chronic low-grade inflammation caused by increased LPS for diabetes treatment. Through certain metabolic pathways, the intestinal microflora can produce short-chain fatty acids, which can protect the intestinal mucosal barrier, regulate host energy intake and metabolism, reduce the level of blood glucose and blood lipids, alleviate chronic low-grade inflammation, and inhibit endotoxins [103, 104]. Animal experiments have proved that the intestinal flora produces butyrate and the content of butyrate in plasma or feces was significantly increased after BBR treatment, confirming that butyrate was an active endogenous metabolite that cooperated with BBR to lower blood lipids [75, 105]. BBR promoted the production of butyric acid bacteria through the acetyl-CoA-butyryl-CoA-butyrate pathway and enables it to synthesize butyrate, and butyrate then entered the blood, thus decreasing blood sugar and blood lipids [97, 104, 106].

Experiment results demonstrated that BBR could improve the intestinal microenvironment, thereby protecting the intestinal barrier function, which may be achieved by regulating intestinal microorganisms [87]. In the diabetic rat model, BBR treatment is efficient in improving endotoxemia, restoring intestinal permeability, and repairing the damaged intestinal mucosa and systemic inflammation by regulating intestinal microflora. Meanwhile, these effects of increasing endocrine regulatory peptide (peptide, PYY), regulating the GLP-1 and GLP-2 secretions, promoting the differentiation of L cells in the colon, and improving the intestinal peptide level in rats fed with a high-fat diet all resulted from BBR [107–109]. Farnesol X receptor (FXR) activation had a pretty favorable effect on the treatment of hyperlipidemia, hyperglycemia, and diabetes [110–112]. Moreover, Sun et al. proved that BBR could activate the FXR signal and directly affect intestinal flora to change bile acid metabolism, thereby improving diabetes and its complications [113].

4. The Interaction between Drugs

Li et al. proposed that the BBR pharmacological effects in vivo weakened after separation and purification. This may be caused by the difference in pharmacokinetic characteristics between purified BBR and BBR in *Rhizoma Coptidis* after intestinal absorption [114]. The difference in BBR pharmacokinetics in vivo may be related to the interaction with other components and drugs. The interaction between them is mainly manifested in various ways discussed in the subsections below.

4.1. P-Glycoprotein. The P-gp substrate is affected by the P-gp efflux. Experiments confirmed that BBR was indeed the P-gp substrate. Due to the P-gp efflux, the BBR concentration in the cell had significantly decreased [115, 116]. The solution to this problem was the synergistic use of P-gp inhibitors and BBR to reduce the BBR efflux and improve BBR absorption [5]. For example, the combination with P-gp inhibitors (e.g., tetrandrine) could enhance the hypoglycemic effect, thereby dramatically improving the pharmacokinetics [22]. The P-gp inhibitor D-α-tocopherol polyethylene glycol-1000 succinate can significantly promote BBR absorption, which contributed to improving poor BBR bioavailability [23]. A Caco-2 cell monolayer test indicated that glycyrrhizin acid could promote BBR permeability through inhibiting P-gp [24]. In addition, the P-gp inhibitor cyclosporine A reduced the BBR efflux rate by more than 30 times [25]. Similarly, in in vitro experiments, oligomeric proanthocyanidins significantly reduced the P-gp expression, increased the average maximum BBR concentration, and promoted the BBR uptake. This led to improving pharmacokinetics in vivo [26].

4.2. Cytochrome P450. CYP450 could metabolize a large number of pharmaceutical ingredients with different structures, especially those with low oral bioavailability. BBR was a substrate of CYP450, and its metabolic process was affected by CYP450. CYP450 inhibition could lead to the interaction of drugs, and the CYP450 activity seems to depend on the BBR dose administered. The experiment proved that CYP2D and CYP1A2 played a vital role in the BBR biotransformation. Giving high BBR doses may inhibit the CYP1A2 activity and interfere with the metabolism of other drugs [32, 39]. In other words, the metabolic BBR kinetics combined with other drugs was largely affected by the CYP450 activity [117].

4.3. Organic Cation Transporter and Multidrug and Toxin Efflux. BBR is not only a P-gp substrate but also an organic cation transporter (OCT) 2 and multidrug and toxin efflux (MATE) 1 substrate. Moreover, MATE1 could inhibit BBR efflux at high concentrations, thereby affecting BBR distribution and excretion. It affected BBR distribution in the liver and its bile excretion. Meanwhile, it affected BBR distribution in the kidneys and its excretion to the feces. In addition, MATE1 mediated BBR renal carrier transport. As a specific MATE inhibitor, pyrimethamine could inhibit BBR outflow at high concentrations, thereby decreasing BBR concentration in cells. Similarly, OCT2 mediated BBR renal carrier transport. As an OCT2 inhibitor, corticosterone could inhibit BBR efflux at high concentrations [118, 119]. Experimental studies have found that, in the absence of inhibitors (e.g., pyrimethamine and corticosterone), BBR could induce pharmacokinetic interactions by combining with other drugs to inhibit OCT- and MATE1-mediated transport [120, 121].

4.4. Combination with Other Antidiabetic Western Medicines. Western medicines (e.g., metformin, glipizide, pioglitazone, glibenclamide, sitagliptin, and so on) are all good hypoglycemic drugs. However, the application of western medicine alone has limited therapeutic effects on diabetes. Thus, combining with BBR is a way to enhance the effect. For example, the combined use of BBR and metformin could competitively inhibit organic cation transporters on the cell membrane, increase the absorption of metformin, and better exert its blood-sugar-lowering effect [120]. The BBR and
sitagliptin combination significantly reduced blood sugar and blood lipids and inhibited the secretion of proinflammatory factors [122]. The BBR and glibenclamide combination improves the MDA level better than using it alone, thereby improving oxidative stress [123].

5. Security

According to literature analysis, the occurrence of toxic and adverse reactions was related to the BBR dose. Almost no toxic and side effects were noted at common doses, and only few patients had mild gastrointestinal reactions, including diarrhea and constipation [124–126]. Some experiments have calculated the BBR lethal dose after administration. The measured 50% lethal dose (LD50) and the level of adverse reactions vary greatly depending on the way and the subject of BBR administration. No LD50 was found in the oral administration group. Meanwhile, the LD50 values in the BBR intraperitoneal and intravenous injection were 9.04 and 57.61 mg/kg, respectively. In mice and rats, the lowest levels of BBR maternal toxicity were 841 and 531 mg/kg/day, respectively. Current data proved that no obvious side effects were noted when BBR was used in combination with other drugs [127–129].

6. Conclusions and Future Recommendation

It is worth noting that the effects of berberine in lowering blood sugar, antioxidative stress, and anti-inflammatory response; regulating lipid metabolism; and regulating intestinal flora are not separated but mutually influence and promote each other. Regarding the pharmacokinetic BBR studies, more studies are based on animal experiments, and fewer reports were noted in humans because its pharmacokinetic behavior is unsatisfactory. By analyzing BBR pharmacokinetic absorption, distribution, metabolism, and excretion, the problem of low BBR bioavailability was noted, which is currently the main reason for restricting the BBR application. Fortunately, continuously increasing studies dedicated to solving the poor BBR absorption exists. The article mainly enumerates three methods: altering the delivery system, adjusting the chemical structure, and using it in coadministration with P-gp inhibitors. Regarding BBR metabolism, most studies have shown that it is often metabolized into other products. However, its pharmacological effects may vary after being metabolized into other products. Therefore, how to discover the active BBR metabolites and moderately increase the oral bioavailability of berberine to maximize the effectiveness of the drug will be the focus of follow-up studies.

The BBR mechanism in diabetes treatment has been extensively discussed, mainly focusing on the five aspects of lowering blood sugar, anti-inflammatory, and antioxidative stress and regulating lipid metabolism and intestinal flora. Berberine is involved in these five aspects. The roles of the parties are not separate but mutually influence and promote each other. The activation of some pathways may play multiple roles. For example, the AMPK activation and the SIRT1 expression promotion does not only lower blood sugar but also serve as anti-inflammatory and antioxidative stress. Intestinal flora has attracted increasing attention in recent years. Studies on the correlation between inflammation, oxidative stress, and intestinal flora in diabetes are also increasing. Moreover, the imbalance of intestinal flora in diabetic patients can also lead to low-grade inflammation, oxidative stress, IR, and vice versa. The summary of the BBR antidiabetic mechanism and the summary of pharmacokinetics can provide more ideas for clinical application studies. These studies can support the necessity of long-term BBR use in diabetes treatment and prevention and its complications and have important reference value and preventive measures for clinical medicine. However, through the summary of the mechanism of action, the molecular mechanism of BBR’s antidiabetic is still not deep enough. Some pathways are only possibly effective, and no definite proof has been noted. Therefore, more detailed and in-depth studies are needed in the future.

As for the interaction between BBR and drugs, few studies exist, especially in combination with Western medicine. Most of the studies separately compare the BBR hypoglycemic effects and Western medicines. Some studies have found that the combination of sugar and Western medicine is better than single use. Thus, a combination of the two to improve diabetes is a direction worth studying. Moreover, intestinal flora has attracted increasing attention in recent years. However, studies on BBR regulation of dysbacteriosis and diabetes prevention are not thorough and systematic, and the specific mechanism and material basis are unclear. Studies in this area are more limited to pharmacodynamic indicators. In addition, the effective pathways and targets are unclear. Therefore, more attention should be focused on the mechanism in the future. Multigroup combination techniques (e.g., metabonomics, macrogenomics, and proteomics) can be used to understand the pathogenesis of the disease from the perspective of the overall metabolism, clarify the specific targets and pathways of BBR intervention, and further verify it at the gene and protein levels. Based on the current study status, it is recommended that the changes in the intestinal flora after BBR intervention should be carried out in depth and systematically, and the correlation with diabetes should be analyzed in depth so that finding active ingredients or component groups with definite effects and clear mechanisms would become easier.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Yunfeng Han conceived the idea and designed the manuscript, worked collaboratively in searching and gathering the literature, and cowrote the manuscript; Xianrong Lai conceived and designed the study; and Yunan Xiang, Yi Shi, Xi Tang, Lin Pan, Jie Gao, and Ruohong Bi amended the paper.
Acknowledgments

This research was funded by the National Natural Science Foundation of China (nos. 81774007, 81473427, 81173360, and 81560806), National Key R&D Projects (2017YFC1703904), and Key Project of Sichuan Provincial Education Department (16ZA0120).

References

[1] B. Pang, L. H. Zhao, Q. Zhou et al., “Application of berberine on treating type 2 diabetes mellitus,” International Journal of Endocrinology, vol. 2015, Article ID 905749, 12 pages, 2015.
[2] M. Zhang and L. Chen, “Berberine in type 2 diabetes therapy: a new perspective for an old antidiarrheal drug?” Acta Pharmacologica Sinica B, vol. 2, no. 4, pp. 379–386, 2012.
[3] A. Khashayar, Z. Bahari, M. Elliyeh et al., “Therapeutic effects of berberine in metabolic diseases and diabetes mellitus,” Revista Brasileira de Farmacognosia, vol. 31, pp. 272–281, 2021.
[4] S. Habtemariam, “Berberine pharmacology and the gut microbiota: a hidden therapeutic link,” Pharmacological Research, vol. 155, Article ID 104722, 2020.
[5] C.-S. Liu, Y.-R. Zheng, Y.-F. Zhang, and X. Y. Long, “Research progress on berberine with a special focus on its oral bioavailability,” Fitoterapia, vol. 109, pp. 274–282, 2016.
[6] S. Habtemariam, “The quest to enhance the efficacy of berberine for type-2 diabetes and associated diseases: physicochemical modification approaches,” Biomedicines, vol. 8, no. 4, 2020.
[7] A. Pirillo and A. L. Catapano, “Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies,” Atherosclerosis, vol. 243, no. 2, pp. 449–461, 2015.
[8] H. X. Cui, Y. N. Hu, J. W. Li et al., “Preparation and evaluation of anti-diabetic agents of berberine organic acid salts for enhancing the bioavailability,” Molecules (Basel, Switzerland), vol. 24, no. 1, p. 103, 2018.
[9] L. Gupta, A. K. Sharma, A. Gothwal et al., “Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics,” International Journal of Pharmaceutics, vol. 528, 2021.
[10] T. Wang, N. Wang, H. Song et al., “Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine,” European Journal of Pharmaceutical Sciences, vol. 44, no. 1, 2011.
[11] Z. P. Wang, J. B. Wu, Q. Zhou et al., “Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 239749, 5 pages, 2015.
[12] J. T. Yin, Y. T. Hou, Y. Y. Yin et al., “Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect,” International Journal of Nanomedicine, vol. 12, 2017.
[13] F. Yu, M. T. Ao, X. Zheng et al., “PEG-lipid-PGLA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency,” Drug Delivery, vol. 24, no. 1, 2017.
[14] M. Xue, Z. P. Li, L. Zhang et al., “Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice,” International Journal of Nanomedicine, vol. 10, pp. 5049–5057, 2015.
[15] M. A. Elsheikh, Y. S. R. Elnaggar, D. A. Hamdy et al., “Novel cremophorylumicros for improved oral bioavailability of the antineoplastic phtymedicine berberine chloride: optimization and pharmacokinetics,” International Journal of Pharmaceutics, vol. 535, 2018.
[16] L. W. Han, W. L. Sheng, X. B. Li et al., “Novel carbohydrate modified berberine derivatives: synthesis and in vitro anti-diabetic investigation,” MedChemComm, vol. 10, no. 4, 2019.
[17] L. Z. Wang, H. T. Kong, M. Jin et al., “Synthesis of disaccharide modified berberine derivatives and their anti-diabetic investigation in zebrafish using a fluorescence-based technology,” Organic & Biomolecular Chemistry, vol. 18, no. 18, 2020.
[18] W. W. Zhao, H. X. Ge, K. Liu et al., “Nandinine, a derivative of berberine, inhibits inflammation and reduces insulin resistance in adipocytes via regulation of AMP-kinase activity,” Planta Medica, vol. 83, 2017.
[19] N. Türner, J. Y. Li, A. Gosby et al., “Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action,” Diabetes, vol. 57, no. 5, 2008.
[20] S. S. Zhang, X. H. Wang, W. C. Yin et al., “Synthesis and hypoglycemic activity of 9-O- (lipophilic group substituted) berberine derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 19, 2016.
[21] D. D. Li, P. Yu, H. Xu et al., “Discovery of C-9 modified berberine derivatives as novel lipid-lowering agents,” Chemical and Pharmaceutical Bulletin, vol. 69, no. 1, 2021.
[22] Y. Q. Shan, Y. P. Zhu, J. Pang et al., “Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function,” Biological and Pharmaceutical Bulletin, vol. 36, no. 10, pp. 1562–1529, 2013.
[23] W. Chen, Y. Q. Miao, D. J. Fan et al., “Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats,” AAPS PharmSciTech, vol. 12, no. 2, 2011.
[24] X. Qiao, Q. Wang, S. Wang et al., “A 42-markers pharmacokinetic study reveals interactions of berberine and glycyrrhizic acid in the anti-diabetic Chinese medicine formula Gegen-Qinlian decoction,” Frontiers in Pharmacology, vol. 9, p. 622, 2018.
[25] X. F. Zhang, F. R. Qiu, J. Jiang et al., “Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and cotisine: involvement of P-glycoprotein,” Xenobiotics, vol. 41, pp. 290–296, 2011.
[26] H. Y. Zhang, X. P. Wang, T. Wang et al., “Enhancement of berberine hypoglycemic activity by oligomeric proanthocyanidins,” Molecules, vol. 23, 2018.
[27] Y. T. Liu, H. P. Hao, H. G. Xie et al., “Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats,” Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 38, no. 10, pp. 1779–1784, 2010.
[28] X. S. Tan, J. Y. Ma, R. Feng et al., “Tissue distribution of berberine and its metabolites after oral administration in rats,” PLoS One, vol. 8, no. 10, Article ID e77969, 2013.
[29] Y. T. Liu, H. P. Hao, H. G. Xie et al., “Oxidative demethylation and subsequent glucuronidation are the major metabolic pathways of berberine in rats,” Journal of Pharmaceutical Sciences, vol. 98, pp. 4391–4401, 2009.
[30] R. N. Aolga, Y. Fan, Z. Chen et al., “Significant pharmacokinetic differences of berberine are attributable to...
Evidence-Based Complementary and Alternative Medicine

variations in gut microbiota between Africans and Chinese,” Scientific Reports, vol. 6, no. 1, 2016.

[31] K. Wang, L. W. Chai, X. C. Feng et al., “Metabolites identification of berberine in rats using ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 139, pp. 73–86, 2017.

[32] Y. Li, G. Ren, Y. X. Wang et al., “Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes,” Journal of Translational Medicine, vol. 9, p. 62, 2011.

[33] Y. Guo, F. Li, X. C. Ma et al., “CYP2D plays a major role in berberine metabolism in liver of mice and humans,” Xenobiota, vol. 41, no. 11, pp. 1–10, 2011.

[34] Y. Li, H. J. Wang, N. Si et al., “Metabolic profiling analysis of berberine, palmatine, jatrohrrhizine, coptisine and epi-berberine in zebrafish by ultra-high performance liquid chromatography coupled with LTQ Orbitrap mass spectrometer,” Xenobiota: The Fate of Foreign Compounds in Biological Systems, vol. 45, no. 4, 2015.

[35] R. Feng, J. W. Shou, Z. X. Zhao et al., “Transforming berberine into its intestine-absorbable form by the gut microbiota,” Scientific Reports, vol. 5, no. 1, 2015.

[36] J. Y. Ma, R. Feng, X. S. Tan et al., “Excretion of berberine and its metabolites in oral administration in rats,” Journal of Pharmaceutical Sciences, vol. 102, pp. 4181–4192, 2013.

[37] X. C. Feng, K. Wang, S. J. Cao et al., “Pharmacokinetics and excretion of berberine and its nine metabolites in rats,” Frontiers in Pharmacology, vol. 11, Article ID 594852, 2021.

[38] J. Y. Zhou, S. W. Zhou, J. L. Tang et al., “Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats,” European Journal of Pharmacology, vol. 606, no. 1, 2008.

[39] M. Imenshahidi and H. Hosseinzadeh, “Berberis vulgaris and berberine: an update review,” Phytotherapy Research, vol. 30, pp. 1745–1764, 2016.

[40] G. Chandirasagaran, C. Elanchezhiyan, K. Ghosh et al., “Berberine chloride ameliorates oxidative stress, inflammation and apoptosis in the pancreas of streptozotocin induced diabetic rats,” Biomedicine & Pharmacotherapy, vol. 95, pp. 175–185, 2017.

[41] C. F. Cao and M. Q. Su, “Effects of berberine on glucose-lipid metabolism, inflammatory factors and IR in patients with metabolic syndrome,” Experimental and Therapeutic Medicine, vol. 17, no. 4, pp. 3009–3014, 2019.

[42] H. Zhang, J. Wei, R. Xue et al., “Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression,” Metabolism: Clinical and Experimental, vol. 59, pp. 285–292, 2010.

[43] W. J. Kong, H. Zhang, D. Q. Song et al., “Berberine reduces IR through protein kinase C-dependent up-regulation of insulin receptor expression,” Metabolism: Clinical and Experimental, vol. 58, no. 1, pp. 109–119, 2009.

[44] F. H. Geng, G. H. Li, X. Zhang et al., “Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats,” British Journal of Pharmacology, vol. 173, no. 10, pp. 1569–1579, 2016.

[45] J. Y. Zhou, S. W. Zhou, K. B. Zhang et al., “Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats,” Biological and Pharmaceutical Bulletin, vol. 31, pp. 1169–1176, 2008.

[46] X. H. Liu, G. S. Li, H. Zhu et al., “Beneficial effect of berberine on hepatic IR in diabetic hamsters possibly involves in SREBP, LXRα and PPARα transcriptional programs,” Endocrine Journal, vol. 57, pp. 881–893, 2010.

[47] L. Z. Liu, S. C. K. Cheung, L. L. Lan et al., “Berberine modulates insulin signaling transduction in insulin-resistant cells,” Molecular and Cellular Endocrinology, vol. 317, no. 1, pp. 148–153, 2010.

[48] Y. X. Sun, M. F. Xia, H. M. Yan et al., “Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21,” British Journal of Pharmacology, vol. 175, no. 2, pp. 374–387, 2018.

[49] C. H. Chen, Y. B. Zhang, and C. Huang, “Berberine inhibits PTP1B activity and mimics insulin action,” Biochemical and Biophysical Research Communications, vol. 397, pp. 543–547, 2010.

[50] D. Liu, Y. Zhang, Y. Liu et al., “Berberine modulates gut microbiota and reduces IR via the TLR4 signaling pathway,” Experimental and Clinical Endocrinology & Diabetes, vol. 126, no. 8, pp. 513–520, 2018.

[51] Y. S. Wu, Z. M. Li, Y. T. Chen et al., “Berberine improves inflammatory responses of diabetes mellitus in zucker diabetic fatty rats and insulin-resistant HepG2 cells through the PPM1B pathway,” Journal of Immunology Research, vol. 2020, Article ID 2141508, 32 pages, 2020.

[52] Y. Y. Jiang, H. M. Cui, J. L. Wang et al., “Protective role of berberine and coptischinensis extract on T2MD rats and associated islet Rin-5f cells,” Molecular Medicine Reports, vol. 16, no. 5, pp. 6981–6991, 2017.

[53] Y. L. Yu, L. Liu, X. T. Wang et al., “Modulation of gluconol-like peptide-1 release by berberine: in vivo and in vitro studies,” Biochemical Pharmacology, vol. 79, no. 7, pp. 1000–1006, 2010.

[54] L. M. Liu, J. Liu, Y. S. Gao et al., “Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets,” British Journal of Pharmacology, vol. 171, no. 13, pp. 3246–3254, 2014.

[55] Z. Q. Wang, F. E. Lu, S. H. Leng et al., “Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity,” World Journal of Gastroenterology, vol. 14, pp. 6004–6011, 2008.

[56] M. Y. Bai, Y. L. Liu, F. Y. Zhou et al., “Berberine inhibits glucose oxidation and insulin secretion in rat islets,” Endocrine Journal, vol. 65, no. 4, pp. 469–477, 2018.

[57] S. H. Kim, E. J. Shin, E. D. Kim et al., “Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes,” Biophysical Research Communications, vol. 397, pp. 543–547, 2016.

[58] Y. S. Wu, Z. M. Li, Y. T. Chen et al., “Berberine modulates gut microbiota and reduces IR via the TLR4 signaling pathway,” Experimental and Clinical Endocrinology & Diabetes, vol. 126, no. 8, pp. 513–520, 2018.
Evidence-Based Complementary and Alternative Medicine

Journal of Physiology. Endocrinology and Metabolism, vol. 294, no. 1, pp. 148–156, 2008.

M. Xu, Y. Y. Xiao, J. Yin et al., “Berberine promotes glucose consumption independently of AMP-activated protein kinase activation,” PLoS One, vol. 9, no. 7, Article ID e103702, 2014.

Y. Y. Xiao, M. Xu, M. Alimujiang et al., “Bidirectional regulation of adenosine 5′-monophosphate-activated protein kinase activity by berberine and metformin in response to changes in ambient glucose concentration,” Journal of Cellular Biochemistry, vol. 119, no. 12, pp. 9910–9920, 2018.

S. J. Jiang, H. Dong, J. B. Li et al., “Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats,” World Journal of Gastroenterology, vol. 21, pp. 7777–7785, 2015.

X. Xia, J. Yan, Y. Shen et al., “Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis,” PLoS One, vol. 6, no. 2, Article ID e16556, 2011.

S. N. Wei, M. Zhang, Y. Yu et al., “Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate- incubated HepG2 cells through suppression of the HNF-4α miR122 pathway,” PLoS One, vol. 11, no. 3, Article ID e0152097, 2016.

Y. S. Lee, W. S. Kim, K. H. Kim et al., “Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin resistant states,” Diabetes, vol. 55, pp. 2256–2264, 2006.

W. G. Chang, M. Zhang, J. Li et al., “Berberine improves IR in cardiomyocytes via activation of 5′-adenosine monophosphate-activated protein kinase,” Metabolism: Clinical and Experimental, vol. 62, pp. 1159–1167, 2013.

Y. Shan, S. C. Zhang, B. Gao et al., “Adipose tissue SIRT1 regulates insulin sensitizing and anti-inflammatory effects of berberine,” Frontiers in Pharmacology, vol. 11, Article ID 591227, 2020.

G. S. J. Luis and S. R. Manuel, “Molecular basis of insulin action,” Drug News & Perspectives, vol. 20, no. 8, 2007.

J. Yao, W. J. Kong, and J. D. Jiang, “Learning from berberine: treating chronic diseases through multiple targets,” Science China Life Sciences, vol. 58, pp. 854–859, 2015.

Q. Gong, Z. M. Hu, F. F. Zhang et al., “Fibrolast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice,” Hepatology, vol. 64, pp. 425–438, 2016.

N. Shen, Y. Huan, and Z. F. Shen, “Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell,” European Journal of Pharmacology, vol. 694, no. 1–3, pp. 120–126, 2012.

B. S. Ko, S. B. Choi, S. K. Park et al., “Insulin sensitizing and insulinotrophic action of berberine from Cortisid rhizome,” Biological and Pharmaceutical Bulletin, vol. 171, pp. 1431–1437, 2005.

S. R. Ma, Q. Tong, Z. X. Zhao et al., “Determination of berberine-upregulated endogenous short-chain fatty acids through derivatization by 2-bromoacetoephone,” Analytical and Bioanalytical Chemistry, vol. 411, no. 14, pp. 3191–3207, 2019.

Z. Li, Y. N. Geng, J. D. Jiang et al., “Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 289264, 12 pages, 2014.

X. L. Ma, Z. J. Chen, L. Wang et al., “The pathogenesis of diabetes mellitus by oxidative stress and inflammation: its inhibition by berberine,” Frontiers in Pharmacology, vol. 9, no. 14, p. 782, 2018.

T. Lao-ong, W. Chatuphonprasert, N. Nemoto et al., “Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine,” Pharmaceutical Biology, vol. 50, no. 8, pp. 1007–1012, 2012.

W. Chatuphonprasert, T. Lao-Ong, and K. Jarukamjorn, “Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide,” Pharmaceutical Biology, vol. 52, no. 4, pp. 419–427, 2014.

D. L. Chen and K. Y. Yang, “Berberine alleviates oxidative stress in islets of diabetic mice by inhibiting miR-106b expression and up-regulating SIRT1,” Journal of Cellular Biochemistry, vol. 118, no. 12, pp. 4349–4357, 2017.

M. Rezaei, E. Keshtzar, M. J. Khodayar et al., “SirT3 regulates diabetogenic effects caused by arsenic: an implication for mitochondrial complex II modification,” Toxicology Letters, vol. 301, pp. 24–33, 2019.

H. Zhang, Y. Shan, Y. Wu et al., “Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-κB signaling pathway in RAW264.7 cells,” International Immunopharmacology, vol. 52, pp. 93–100, 2017.

G. Chandirasagaran, C. Elanchezhiyan, and K. Ghosh, “Effects of berberine chloride on the liver of streptozotocin-induced diabetes in albino Wistar rats,” Biomedicine & Pharmacotherapy, vol. 99, pp. 227–236, 2018.

L. H. Huang, X. P. Pan, K. R. Gong et al., “Anti-inflammatory effects of three kinds of traditional Mongolian medicine monomer and its combination on LPS-stimulated RAW264.7 macrophages,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 5, pp. 950–958, 2016.

C. F. Mo, L. Wang, J. Zhang et al., “The crosstalk between Nr2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice,” Antioxidants & Redox Signaling, vol. 20, no. 4, 2014.

J. F. Ndsang, “Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity,” Mediators of Inflammation, vol. 2010, Article ID 359732, 18 pages, 2010.

D. H. Li, J. M. Zheng, Y. T. Hu et al., “Amelioration of intestinal barrier dysfunction by berberine in the treatment of nonalcoholic fatty liver disease in rats,” Pharmacognosy Magazine, vol. 13, no. 52, pp. 677–682, 2017.

Y. W. Wang, X. Yi, K. Ghanam et al., “Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption,” Metabolism: Clinical and Experimental, vol. 63, no. 9, pp. 1167–1177, 2014.

W. J. Kong, J. Wei, P. Abidi et al., “Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins,” Nature Medicine, vol. 10, no. 12, pp. 1344–1351, 2004.

Q. Tang, W. Wei, L. M. Chen et al., “Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats,” Journal of Ethnopharmacology, vol. 108, no. 1, pp. 109–115, 2006.

X. Y. Li, Z. X. Zhao, M. Huang et al., “Effect of berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters,” Journal of Translational Medicine, vol. 13, no. 1, 2015.
Evidence-Based Complementary and Alternative Medicine

Q. Zhang, X. H. Xiao, K. Feng et al., “Berberine moderates glucose and lipid metabolism through multipathway mechanism,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 924, 10 pages, 2011.

H. Liang and Y. T. Wang, “Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase Cδ pathway,” Biochemical and Biophysical Research Communications, vol. 498, no. 3, pp. 473–480, 2018.

Y. Wang, Q. Tong, J. W. Shou et al., “Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine,” Theranostics, vol. 7, pp. 2443–2451, 2017.

L. C. Zhang, X. Y. Wu, R. B. Yang et al., “Effects of berberine on the gastrointestinal microbiota,” Frontiers in Cellular and Infection Microbiology, vol. 10, Article ID 588517, 2021.

C. Q. Chen, Z. Yu, Y. Y. Li et al., “Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications,” The American Journal of Chinese Medicine, vol. 42, no. 5, pp. 1053–1070, 2014.

X. Z. Xu, Z. Z. Gao, F. Q. Yang et al., “Antidiabetic effects of Gegen Qinlian decoction via the gut microbiota are attributable to its key ingredient berberine,” Genomics, Proteomics & Bioinformatics, vol. 18, 2020.

W. Li and D. Andrew, “Factors influencing the gut microbiota, inflammation, and type 2 diabetes,” The Journal of Nutrition, vol. 147, no. 7, pp. 1468–1475, 2017.

F. Guanner and J. R. Malagelada, “Gut flora in health and disease,” The Lancet, vol. 361, no. 9356, pp. 512–519, 2003.

M. Li, X. B. Shu, H. C. Xu et al., “Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds,” Journal of Translational Medicine, vol. 14, no. 1, p. 237, 2016.

Y. Cao, Q. Pan, W. Cai et al., “Modulation of gut microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice,” Archives of Iranian Medicine, vol. 19, no. 3, pp. 197–203, 2016.

S. H. Gu, B. Cao, R. B. Sun et al., “Metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of oral-administered berberine,” Molecular Biosystems, vol. 11, no. 2, pp. 463–474, 2015.

G. Besten, K. Eunen, A. K. Groen et al., “The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism,” Journal of Lipid Research, vol. 54, no. 9, pp. 2325–2340, 2013.

Y. Wang, J. W. Shou, X. Y. Li et al., “Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism,” Metabolism: Clinical and Experimental, vol. 70, pp. 72–84, 2017.

R. Feng, Z. X. Zhao, S. R. Ma et al., “Gut microbiota-regulated pharmacokinetics of berberine and active metabolites in Beagle dogs after oral administration,” Frontiers in Pharmacology, vol. 9, p. 214, 2018.

X. M. Xu, H. Yi, J. Š. Wu et al., “Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence,” Biomedicine & Pharmacotherapy, vol. 133, 2021.

M. Li, W. J. Zhou, Y. Q. Dang et al., “Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice,” Biomedicine & Pharmacotherapy, vol. 132, 2020.

C.Y. Shan, J. H. Yang, Y. Kong et al., “Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats,” The Journal of Endocrinology, vol. 218, no. 3, pp. 255–262, 2013.

J. H. Xu, X. Z. Liu, W. Pan et al., “Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels,” Molecular Medicine Reports, vol. 15, no. 5, pp. 2765–2787, 2017.

Y. Q. Zhang, F. Y. Lee, G. Barrera et al., “Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 4, pp. 1006–1011, 2006.

A. H. Ali, E. J. Carey, and K. D. Lindor, “Recent advances in the development of farnesoid X receptor agonists,” Annals of Translational Medicine, vol. 3, no. 1, 2015.

J. P. Arab, S. J. Karpen, P. A. Dawson et al., “Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives,” Hepatology, vol. 65, pp. 350–362, 2017.

R. Sun, N. Yang, B. Kong et al., “Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway,” Molecular Pharmacology, vol. 91, no. 2, pp. 110–122, 2017.

Q. Li, Y. Yang, T. Zhou et al., “A composutive strategy to study the pharmacokinetics of TCMs: taking Cortisoid rhi-zoma, and Cortisoid rhi-zoma-Glycyrrhizae radix et rhi-zoma as examples,” Molecules, vol. 23, p. 2042, 2018.

G. Y. Pan, G. J. Wang, X. D. Liu et al., “The involvement of P-glycoprotein in berberine absorption,” Pharmacology & Toxicology, vol. 91, no. 4, pp. 193–197, 2002.

Y. T. Zhang, Y. Q. Yu, X. Y. Yan et al., “Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity,” Acta Pharmacologica Sinica, vol. 40, no. 1, pp. 133–142, 2019.

B. Jiang, L. Y. Meng, F. Zhang et al., “Enzyme-inducing effects of berberine on cytochrome P450 I42 in vitro and in vivo,” Life Sciences, vol. 189, pp. 1–7, 2017.

R. Shi, Y. Y. Yang, Z. Y. Xu et al., “Renal vectorial transport of berberine mediated by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 (MATE1) in rats,” Biopharmaceutics & Drug Disposition, vol. 39, no. 1, pp. 47–58, 2018.

I. Oh, H. Chung, S. I. Park et al., “Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycemic activity in humans,” Diabetes, Obesity and Metabolism, vol. 18, no. 1, pp. 104–108, 2016.

M. Kwon, A. Choi, M. K. Choi et al., “Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin,” Archives of Pharmacal Research, vol. 38, no. 5, pp. 849–856, 2015.

R. Shi, Z. Y. Xu, X. N. Xu et al., “Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine,” European Journal of Pharmaceutical Sciences, vol. 127, pp. 282–290, 2018.

S. Mehrdoost, P. Yahaghami, H. Jafary et al., “The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease,” Iranian Journal of Basic Medical Sciences, vol. 24, no. 4, 2021.

C. Waranya, L. Thinnakorn, and J. Kanokwan, “Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2 diabetes in mice by berberine and glibenclamide,” Pharmaceutical Biology, vol. 52, no. 4, 2013.
[124] J. R. Lan, Y. Y. Zhao, F. X. Dong et al., “Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension,” *Journal of Ethnopharmacology*, vol. 161, pp. 69–81, 2015.
[125] M. Imenshahidi and H. Hosseinzadeh, “Berberine and barberry (Berberis vulgaris): a clinical review,” *Phytotherapy Research*, vol. 33, no. 3, pp. 504–523, 2019.
[126] W. H. Chueh and J. Y. Lin, “Protective effect of berberine on serum glucose levels in non-obese diabetic mice,” *International Immunopharmacology*, vol. 12, no. 3, pp. 534–538, 2012.
[127] G. D. Jahnke, C. J. Price, M. C. Marr et al., “Developmental toxicity evaluation of berberine in rats and mice,” *Birth Defects Research. Part B, Developmental and Reproductive Toxicology*, vol. 77, no. 3, pp. 195–206, 2006.
[128] M. M. Kheir, Y. G. Wang, L. Hua et al., “Acute toxicity of berberine and its correlation with the blood concentration in mice,” *Food and Chemical Toxicology*, vol. 48, no. 4, 2010.
[129] S. A. Almani, I. A. Memon, T. Z. Shaikh et al., “Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus,” *Iranian Journal of Basic Medical Sciences*, vol. 20, no. 5, pp. 511–515, 2017.